基本信息
浏览量:768
职业迁徙
个人简介
Dr. Witzig has research interests in Hodgkin and non-Hodgkin lymphoma, multiple myeloma, and chronic lymphocytic leukemia. His laboratory research centers around the study of new agents that interfere with signal transduction pathways in lymphoma and myeloma cells. This has led to clinical trials of new agents that focus on the PI3 kinase signal transduction pathway. These agents include temsirolimus and everolimus. He has also been involved in some of the first studies of lenalidomide for lymphoma. He has a long-standing interest in radioimmunotherapy and is conducting new research that combines immunomodulatory agents with Zevalin radioimmunotherapy.
研究兴趣
论文共 304 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
JCO oncology practicepp.OP2300628-OP2300628, (2024)
Chonlada Laoruangroj,Pamela J. Atherton,Gregory A. Wiseman,Stephen Ansell,Andrew L. Feldman, Peyton Schumacher,Thomas E. Witzig
LEUKEMIA & LYMPHOMAno. 3 (2024): 333-338
Cell reports. Medicineno. 3 (2024): 101443-101443
Blood Advancesno. 5 (2024): 1250-1257
Angelo Ciaraglia, Eri Osta, Hanzhang Wang,Francisco Cigarroa,Elizabeth Thomas,Danielle Fritze,Susannah Nicholson,Brian Eastridge,Victor A. Convertino
SHOCKno. 1 (2024): 61-67
Chonlada Laoruangroj,Thomas M. Habermann,Yucai Wang,Rebecca L. King,Scott C. Lester,Carrie A. Thompson,Thomas E. Witzig
JCO Oncology Practice (2024)
Chonlada Laoruangroj,Thomas M Habermann,Yucai Wang,Rebecca L King,Scott C Lester,Carrie A Thompson,Thomas E Witzig
JCO oncology practicepp.OP2300624-OP2300624, (2024)
Blood (2023): 1657
BLOOD (2023): 4569
Jacob Shreve,Allison M. Bock, Izel Okcu,Antonious Hazim,Joshua C. Pritchett,Raphael Mwangi,Matthew J. Maurer,Mithun V. Shah,Yucai Wang, Stephen M. Ansell,Thomas M. Habermann,Thomas E. Witzig,
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn